Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus

Verify with FDA CVM →

36 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
7
Deaths Reported
1940.0%
Death Rate

Active Ingredients

Equine Influenza Virus, Killed VirusEquine Rhinopneumonitis Virus, Killed Virus

Administration Routes

IntramuscularNasalUnknown

Species Affected

Horse 36

Most Affected Breeds

Quarter Horse 13
Horse (unknown) 4
Arab 3
Thoroughbred 2
Pura Raza Española (Andalusian) 2
Paint 2
Saddlebred - American 1
Crossbred Equine/horse 1
Welsh Mountain Pony 1
Horse (other) 1

Most Reported Reactions

Lack of efficacy - NOS 8
Fever 6
Other abnormal test result NOS 6
Colic 6
Anorexia 6
Depression 5
Injection site pain 4
Death by euthanasia 4
Nasal discharge 3
Lameness 3
Injection site swelling 3
Rolling 3

Outcome Breakdown

Recovered/Normal
19 (51.4%)
Outcome Unknown
6 (16.2%)
Ongoing
5 (13.5%)
Euthanized
4 (10.8%)
Died
3 (8.1%)

Data Summary

Metric Value
Total adverse event reports 36
Reports involving death 7
Case-fatality rate (reported events) 1940.0%
Distinct species in reports 1
Distinct breeds in reports 16
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 36 adverse event reports referencing Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus, including 7 reports in which the animal died — a 1940.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Equine Influenza Virus, Killed Virus, Equine Rhinopneumonitis Virus, Killed Virus. Reported administration routes include Intramuscular, Nasal, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus reports are Horse (36 reports), with Horse accounting for the largest share. Within those species, Quarter Horse (13), Horse (unknown) (4), Arab (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus are Lack of efficacy - NOS (8), Fever (6), Other abnormal test result NOS (6), Colic (6). Of the 37 reports with a coded outcome, Recovered/Normal is the leading category at 51.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Equine Influenza Virus, Killed Virus + Equine Rhinopneumonitis Virus, Killed Virus.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial